Summary of MaxCyte (MXCT) Q3 2025 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $6.8 million, down from $8.2 million in Q3 2024.

Core Revenue: $6.4 million, compared to $8.1 million in the prior year.

Revenue Breakdown:

Instrument Revenue: $1.4 million (down from $1.8 million).

License Revenue: $1.8 million (down from $2.5 million).

Processing Assembly (PA) Revenue: $2.6 million (down from $3.4 million).

Gross Margin: 77%, slightly up from 76% year-over-year; non-GAAP adjusted gross margin at 81%, down from 85%.

Operating Expenses: $19.4 million, down from $20.3 million, including $3.1 million in restructuring charges.

Cash Position: $158 million in cash, equivalents, and investments, with no debt.

2Strategic Updates and Business Highlights

Signed a new strategic platform license (SPL) with Moonlight Bio, bringing the total SPLs signed in 2025 to four.

SeQure DX is fully integrated, with positive market validation expected to drive long-term opportunities.

14 SPL customers have 18 active clinical programs, with five expected to enter pivotal studies in the next 6 to 18 months.

The company underwent a restructuring initiative, reducing its workforce by 34% to enhance operational efficiency and align spending with market conditions.

Anticipated annualized savings from restructuring between $17 million and $19 million.

3Forward Guidance and Outlook

Reiterated guidance for 2025, expecting core revenue to be flat to a 10% decline compared to 2024.

SPL program-related revenue projected to be approximately $5 million in 2025.

Expected cash burn of $10 million to $15 million in 2026, with improvements anticipated as customers progress through clinical programs.

Confidence in signing 3 to 5 new SPLs annually for the foreseeable future.

4Bad News, Challenges, or Points of Concern

Revenue decline attributed to timing of instrument orders and a challenging operating environment, particularly affecting key customers.

The funding environment for ex vivo therapies remains depressed, impacting commercial adoption and customer spending.

The restructuring, while aimed at improving efficiency, reflects ongoing operational challenges and market pressures.

Some customers have rationalized programs, which may continue to affect growth in the first half of 2026.

5Notable Q&A Insights

Management expressed cautious optimism about stabilization in the biotech funding environment, though they remain prepared for continued challenges.

No indications from customers that FDA leadership changes would delay program timelines; confidence remains in the approval process.

SeQure DX is expected to ramp up in 2026, with a larger customer funnel compared to the previous year.

The company is actively pursuing M&A opportunities to enhance its platform and consolidate its position in the cell and gene therapy space.

Confidence in future SPL signings is based on ongoing collaborations and support for customers in their preclinical and IND filing processes. Overall, while MaxCyte faces headwinds from a challenging market and restructuring efforts, it maintains a positive outlook on its strategic initiatives and long-term growth potential in the cell and gene therapy sector.